The firm is developing a sepsis and SIRS diagnostic that combines its own molecule counting technology with Thermo Fisher's procalcitonin assay.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
Thermo Fisher said the deal strengthens its portfolio for stem cell research, and it will fold MTI-GlobalStem into its life sciences solutions segment.
Thermo Fisher developed the NGS-based multi-marker assay in collaboration with Novartis and Pfizer to match lung cancer patients with targeted drugs.
Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
During the company's third quarter earnings call, CEO Mark Casper highlighted a number of recent clinical and diagnostic product launches and initiatives.
The company saw growth in all four of its segments, in particular from life sciences solutions and analytical instruments.
The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.
Their method uses the increased separation provided by FAIMS upfront of mass spec analysis, to reduce precursor interference in isobaric tagging experiments.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.